Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes
2008
Targeting GLP-1 Release for Type 2 Diabetes Therapy
publication
Evidence: moderate
Author Information
Author(s): F. M. Gribble
Primary Institution: Cambridge Institute for Medical Research
Hypothesis
Can enhancing GLP-1 release improve glycaemia in Type 2 diabetes?
Conclusion
Enhancing GLP-1 secretion may provide new therapeutic strategies for managing Type 2 diabetes.
Supporting Evidence
- GLP-1 and GIP are important for insulin release after eating.
- GLP-1 mimetics have been developed for Type 2 diabetes treatment.
- Chronic GLP-1 therapy can lead to weight loss.
Takeaway
GLP-1 is a hormone that helps control blood sugar and appetite, and finding ways to boost its levels could help people with diabetes.
Methodology
The article reviews existing studies on GLP-1 and its effects on insulin release and appetite regulation.
Limitations
The full biological consequences of chronic DPP-4 inhibition remain uncertain.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website